Next Generation Sequencing Archives - Evolution Search Partners

October 24, 2018

Categories

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]

August 10, 2018

Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Categories

News & Analysis

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]

March 27, 2018

Categories

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]

July 14, 2017

Categories

Looking Beyond Genomics: A Holistic Approach to Precision Medicine

[vc_row][vc_column][vc_column_text] England’s Chief Medical Officer, Dame Sally Davies, recently called for making genomic testing as common as blood tests in order to usher in the era […]

January 11, 2017

Illumina’s NovaSeq Platform Aims for the $100 Human Genome, but is it Good Business?

Categories

News & Analysis

Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation?

Illumina utilised their showcase at the JP Morgan Conference to announce its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the […]

March 17, 2016

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

Categories

News & Analysis

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for […]

February 2, 2016

Categories

News & Analysis

To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing

The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of […]

January 12, 2016

Evolution Analysis: Thermo Fisher to Acquire Affymetrix

Categories

News & Analysis

Evolution M&A Analysis: Thermo Fisher to Acquire Affymetrix for $1.3 billion

Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously […]

October 28, 2015

The Role of Metagenomic Analysis in Drug Development

Categories

News & Analysis

The Role of Metagenomic Analysis in Drug Development

In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. […]